| 货号 | 13647-25mg |
| 描述 | AZD 1152 is an orally bioavailable prodrug of AZD 1152-HQPA, a selective inhibitor of Aurora kinase B (IC50 = 0.36 nM).1 AZD 1152 is converted to AZD 1152-HQPA in plasma. Inhibition of Aurora B results in disruption of spindle checkpoint functions and chromosome alignment, resulting in inhibition of cytokinesis followed by apoptosis.2,3 AZD 1152 inhibits tumor xenograft growth in vivo.4,5 |
| 别名 | Barasertib; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Mortlock, A.A.,Foote, K.M.,Heron, N.M., et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J. Med. Chem. 50(9), 2213-2224 (2007). 2.Popescu, R.,Heiss, E.H.,Ferk, F., et al. Ikarugamycin induces DNA damage, intracellular calcium increase, p38 MAP kinase activation and apoptosis in HL-60 human promyelocytic leukemia cells. Mutation Research 709-710, 60-66 (2011). 3.Moore, A.S.,Blagg, J.,Linardopoulos, S., et al. Aurora kinase inhibitors: Novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia 24(4), 671-678 (2010). 4.Wilkinson, R.W.,Odedra, R.,Heaton, S.P., et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin. Cancer. Res 13(12), 3682-3688 (2007). 5.Yang, J.,Ikezoe, T.,Nishioka, C., et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 110(6), 2034-2040 (2007). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥95% |
| 计算分子量 | 587.5 |
| 分子式 | C26H31FN7O6P |
| CAS号 | 722543-31-9 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |